During the last two decades considerable advances have been made in the understanding of the biology of RCC. Although the best therapeutic options for patients with metastatic RCC have not been defined, it is apparent that use of immunomodulating cytokines like interferon-alpha and interleukin-2 either alone or combined with chemotherapeutic agents provides the best available results in routine clinical practice. Numerous studies have confirmed that objective tumour responses are seen only in a small fraction of patients (averagely in 15-20 %). In spite of a lot of evidence that these treatments prolong survival, expectations of only 5-10 % long-term survivals with complete and durable regression of tumours are realistic. Recently, some new promising investigational approaches have been reported. These may already in near future further improve overall treatment results.
INTRODUCTION
At the time of diagnosis of renal cell carcinoma (RCC) approximately 30 % of patients have a metastatic disease and further 30 % to 40 % develop metastases in the months or years after nephrectomy. Among individuals with metastatic disease, about 75 % exhibit lung metastases, 36 % have lymph node and/or soft tissue involvement, 20 % have bone involvement, 18 % have liver metastases, and <10 % have metastases in the central nervous system or skin. The prognosis for patients with metastatic disease has been generally poor with a median survival less than 12 months depending greatly on patient's initial status (prognostic factors). On the other hand, from the last decade there are a number of studies including treatment with biological response modifiers like inter-feron (IFN) and interleukin-2 (IL-2) reporting median survival of patients from 15 to 20 months and a small fraction of patients with long-term survival. Thus, the clinical outcome may depend on patient related factors like age and general condition as well as extent and location of the disease and biological aggressiveness of tumours, but also selection of the therapy. Studies have demonstrated that increased survival in patients with metastatic disease occurs under the following conditions: The presence of a long disease free interval between nephrectomy and the onset of metastasis, presence of pulmonary metastases only, good performance status, and removal of primary tumour.
For clinical use and also enabling to compare treatment results of different clinical trials, a number of prognostic and risk group analyses have been reported in the literature. Motzer and coworkers (1) defined from nine variables five the most significant risk factors that predicted survival among patients treated with interferon. These were haemoglobin, LDH, corrected calcium, Karnofsky performance status, and interval from diagnosis to treatment. Finally, each patient was assigned to one of these risk groups: Those with zero risk factors (favourable risk), those with one or two (intermediate risk), and those with three or more (poor risk). Since patient population within different studies may be greatly variable, uniform use of this kind of prognostic evaluations would be of great importance for comparisons of the results of new experimental treatments in different studies.
CHEMOTHERAPY
RCC is one of the most chemoresistant tumours. Most cytotoxic agents, at some stage in their development, have been evaluated in phase I/II trials in RCC, but mainly the results have been disappointing. In a review by Yagoda et al.
(2) among 4093 evaluable patients in 83 clinical trials published from 1983 to 1993, a 6 % response rate was reported including 53 complete responses (1.3 %). The drugs with modest activity in this analysis were floxuridine, 5-fluorouracil (5-FU), and vinblastine demonstrating average response rates 12 %, 10 %, and 7 %, respectively. The results of the vinblastine have been still more discouraging since that analysis with reported response rates less than 3 % (3).
Since infusional 5-FU demonstrates some activity it has been rational to test also a new generation of fluoropyrimidines, capecitabine, in RCC. This is an orally administered fluoropyrimidine carbonate activated by a three-step enzymatic conversion to the cytotoxic agent 5-FU. The last step of enzymatic activation is mediated by thymidine phosphorylase, which is highly present in tumour tissue. Therefore, 5-FU is also in remarkably higher concentrations in tumour tissues compared to corresponding normal tissues. Wenzel and coworkers (4) could demonstrate significant activity of this drug among 26 patients with metastatic RCC in which first-or second-line immunotherapy treatment had failed. Two (8.5 %) out of 23 assessable patients had a partial response, 5 (21.7 %) minor response, and disease stabilization was seen in 13 (56.5 %) of the patients. Since the drug can be easily administered on outpatient setting and has a favourable toxicity profile the efficacy should be further evaluated in first-and second-line treatment as monotherapy as well as in combination with immunotherapy agents.
Combination chemotherapy has also been largely unsuccessful, with no regimen showing superiority to single-agent therapy. One phase II trial evaluated weekly gemcitabine plus continuous infusion of 5-FU (5). Forty-one patients were treated, 80 % of them had multiple metastatic site and 83 % of them had received previous treatment. 17 % of the patients had a partial response, and median progression-free survival was 28.7 weeks. This can be considered an interesting result, particularly in this kind of patient population and should be further tested in larger patient groups replacing also 5-FU with capecitabine.
HORMONAL THERAPY
Hormonal treatments have been used for RCC for several decades. Efficacy of progestional agents to inhibit the growth of diethyl stilboestrol induced renal carcinoma in Syrian hamsters raised interest in these agents in human RCC. Also oestrogen, progesterone and testosterone receptors may be found in RCC. Some of the early clinical trials on the use of progestins in RCC provided some positive results. Subsequent studies reported response rates varying between 5 to 10 %, but usually of short duration and only for patients with lung metastases. When strict response criteria were used the objective response rate is less than 5 %. Despite the available fairly negative data, progesterone therapy is still often used in advanced RCC, mostly perhaps due to additional effects of therapy, such as increased appetite and weight gain improving patients' quality of life.
A study with high dose tamoxifen reported a 12 % response rates with a median duration of response of 20 months (6). Similarly, with another antioestrogenic drug, toremifene at high doses a 17 % response rate was reported including one complete response among the 36 patients (7). These observations still await confirmation from other research groups.
INTERFERON THERAPY
Antitumour activity of interferon against renal cell carcinoma was initially reported 1983 with a partially purified recombinant human interferon (IFNα ). The overall response rate in 1042 patients treated with either of the two commercially available IFNα preparations has been 12 %. Factors that seem to increase the likelihood of responses include good performance status, prior nephrectomy, and metastases confined to the lungs. Also a modest survival benefit has been documented in two randomized phase III trials (3, 8).
A randomized comparison of IFNα versus medroxyprogesterone acetate among 335 patients in U.K. demonstrated a significant prolongation of median survival (6 months for medroxyprogesterone and 8.5 months for IFN) (8). When comparing the results to other studies one should note that planned maximal IFN treatment period was only 12 weeks, maximally in dose 10 MU three times a week. In the Finnish multicentre study comparing IFNα -2a plus vinblastine to vinblastine alone we could demonstrate significant prolongation of median survival from 37.8 to 67.6 weeks attributed to IFN (3). In this study the planned maximal duration of IFN-treatment was 12 months, although only 23 % of the patients were treated that period or in 6 cases even longer. Also the planned weekly dose was higher (18 MU three times a week) than in the British study. The response rate in the IFN-containing arm was 16.5 % but only 2.5 % in the vinblastine arm, confirming also the results from many other previous studies.
Although IFNα has been explored in metastatic RCC for two decades in thousands of patients there exists still a great controversy about the optimal scheduling and duration of treatment. Randomized prospective studies comparing different dosage have suggested that a dose of 2 MU/m 2 /day was not sufficient. It is generally accepted that the interferon dose of 5-10 MU should be given at least 3 times per week. Some small studies have reported higher response rates when even higher doses are used. Earlier studies also revealed that the benefit of IFN therapy in terms of response should be seen already in the early treatment period. That might not be true. To clarify more the optimal dosing, a treatment protocol was designed with escalating dose from 4.5 MU to the maximal tolerable dose of 9, 12, 13.5 or 18 MU three times a week (9). The individually selected tolerated dose was then continued with a 3-week intermittent schedule followed by a 1-week pause every fourth week. The treatment was planned to be continued up to 2 years provided no disease progression or substantial side effect appeared. In a phase II study this regimen appeared to be feasible demonstrating a response rate of 17 % including 5complete responses and 8 partial responses. Interestingly, we observed three late objective responses (4 %) occurring after 12 month treatment. The median progression free time of all the patients was 12.3 months, and median survival time 19.3 months. Thus, the conclusion is that when IFNα is used alone a prolonged treatment duration of more than 12 months for stable and responding patients is beneficial and may improve the outcome with prolongation of survival.
Since the standard commercially available IFNα preparations are characterized by a relatively short plasma half-life requiring frequent dosing, new modes of pegylated interferons (PEG-IFN) have been developed, enabling less frequent dosing. In PEG-IFN interferon is chemically modified by the covalent attachment of polyethylene glycol (PEG) moiety to enhance pharmacokinetic characteristics and reduce immunogenity. These are now commercially available from both IFNα -2a and IFNα -2b. The sustained maintenance of serum levels of IFN allows once-weekly dosing of PEG-IFN. Also two randomized trials showed PEG-IFN to be more effective than standard IFNα and well tolerated in treatment of patients with hepatitis C. Both pegylated IFNα -2a and -2b have now been preliminary tested in advanced RCC (10, 11) . The efficacy and tolerability profiles were similar to standard IFNα s and adverse events were mostly mild to moderate. If the subsequent studies confirm these observations PEG-IFNs may in near future replace the use of standard IFN in RCC.
Except IFNα there exist also beta and gamma interferons (IFNβ , IFNγ ). Both of these have also been tested for advanced RCC. IFN β has only a limited data investigating its use in RCC. Combined data from three studies in late 80s including a total of 56 assessable patients showed response rate from 6-20 %, fairly similar to IFNα . However, further research in RCC has not been conducted. Also research interest in the use of IFNγ in RCC was totally stopped in mid 90s after two negative reports by two separate research groups, although previously some efficacy was described in patients with limited metastases.
CHEMOTHERAPY COMBINED WITH INTERFERON
Numerous trials have been conducted combining interferon with chemotherapy, mainly with vinblastine. Wirth (12) reported 11 trials including 315 patients where vinblastine was combined with IFN-α . The response rate ranged from 0 to 45 %. However, two randomized trials could not demonstrate any significant benefit of combining vinblastine with interferon (13) . Interferon has also been combined with floxuridine or 5-FU with some early promising reports. However, multi-institutional studies could not demonstrate any remarkable benefit from combining interferon with these drugs.
INTERLEUKIN-2 THERAPY
Interleukin-2 (IL-2) was discovered in 1976. Its activity was demonstrated as a T-cell growth factor and activator of T-cells and natural killer cells. IL-2 has been used in clinical trials against different types of malignancies. Its activity in RCC was documented first in 1984. Using maximally tolerated dose the early trials initially reported response rates up to 33 %, but in the subsequent multicentre study the response rate was 16 % (14). One of the remarkable features was that many of these responses were complete and durable. Long-term analyses from these early trials also demonstrate that 7 to 9 % of all patients had complete response and majority of these patients have never relapsed. These evidences of the clinical benefit of IL-2 without any phase III studies led to the approval of IL-2 by U.S. Food and Drug Administration as the only approved drug therapy for RCC in the United States in 1992.
The severity and nature of the side effects of IL-2 are directly related to the dose and schedule. High dose i.v. schedules are associated with a higher incidence of side effects when contrasted with lower dose or subcutaneous schedules (14) . Patients regularly develop fever, chills, and malaise, as well as vascular leak syndrome characterized by weight gain, oliguria, tachycardia and hypotension. Also various organ dysfunctions are frequent like cardiac and cardiovascular dysfunctions including arrhythmias as well as gastrointestinal and neurologic symptoms. Haematopoetic findings include anemia, thrombocytopenia, and leucopenia and an increased frequency of septic infections. Fortunately, the side effects are generally self-limited and resolve rapidly after discontinuation of IL-2 therapy. Several strategies have been proposed for improving the antitumour activity of IL-2 for reducing toxicity. The initial reports from trials involved a high-dose bolus i.v. injection with the most pronounced toxic effects. In the subsequent studies IL-2 has been administered as continuous infusions or subcutaneous injections and recently also in inhalated form (14, 15) . Also combining with interferon alfa was supposed to be beneficial enabling to reduce IL-2 dose.
INTERLEUKIN-2 AND INTERFERON-ALPHA COMBINATION THERAPY
Preclinical murine tumour models have demonstrated the synergistic antitumour effects of combining IFNα and IL-2 therapy, although the mechanisms of synergy remain unknown. This is the rationale background for their combined use in humans. This expectation for potential synergy resulted in a large number of phase I and II clinical trials to test the efficacy and toxicity of this combination in the treatment of advanced RCC. This IFNα and IL-2 combination therapy has been administered on a variety of dose levels and IL-2 has been given either as a continuous infusion, bolus injections or subcutaneously. Altogether these numerous phase I and II trials demonstrated response rate of approximately 20 % in over 1200 patients (14, 16) . Also two randomized trials have compared IL-2 treatment with or without IFNα . Atkins et al (17) used high dose IL-2 and i.v. IFNα . The response rate was 11 % for the combination and 17 % for single agent IL-2. The difference was not statistically significant. In a randomized multicentre phase III trial comparing continuous i.v. infusion IL-2 versus s.c. IFNα versus both, response rates after 10 weeks were 6.5 % with IL-2, 7.5 % with IFNα , and 18.6 % with the combination (18) . However, no difference in overall survival was observed, possibly because of the cross-over allowed between the two monotherapy arms in the event of tumour progression. Thus, in spite of numerous phase I-III studies on IL-2/IFN combinations it is not clear whether cytokine combination therapy improves effectiveness of these drugs and is warranted, especially when balanced against the apparently increased toxicity of such treatments. Concerning the tolerability of IL-2 treatment interesting results have been reported by Buzio and coworkers (19) . They administered low-dose IL-2 combined with low-dose IFN, the doses being about 1/5 from many other protocols. The treatment-related toxicity was mild and limited to WHO grades 1 and 2. The overall response rate was 12 % and 36-month survival probability for all 50 patients was 47 %. These interesting findings warrant confirmation in a larger patient population.
INTERLEUKIN-2 AND INTERFERON COMBINED WITH CHEMOTHERAPY
The possible therapeutic synergism of cytokines and chemotherapeutic agents has also been explored, fluorouracil (5-FU) being the cytotoxic agent most extensively studied. Particularly, the German study group has focused on subcutaneously administered IL-2/IFN based home therapy combined with 5-FU. Recently Atzpodien and coworkers (20) reported their thirteen-year experiences of the IFNα and IL-2 based home therapy of 443 patients with advanced RCC. Majority of these patients (n = 260) received i.v. 5-FU and part of them (n = 86) also 13 cis-retinoic acid. The average response rate in this fairly selected patient population was 28.5 % including 37 (8.4 %) complete responses. The median overall survival was 21+ months. The long-term follow-up of these patients showed 13-year survival rate to be about 9 %. The study provides evidence of long-term benefit in a subset of patients with good or excellent performance status, who have advanced RCC. Recently the study group confirmed their favourable results in a randomized phase III study, where s.c. IL-2 plus s.c. IFNα combined with 5-FU either with or without 13 cis-retinoic acid improved progression-free survival and overall survival compared to s.c. IFNα and vinblastine combination (21) . However, these favourable results in combining 5-FU with subcutaneous IFNα and IL-2 have not been confirmed by many other study groups, e.g. Negrier et al. (22) .
ANTIANGIOGENIC TREATMENT
Inhibition of tumor angiogenesis is an attractive approach in the treatment of metastatic RCC. Studies of the hereditary form of clear-cell carcinoma, occurring in the von Hippel-Lindau syndrome, led to the identification of the von Hippel-Lindau tumour suppressor gene (VHL). The alterations of this tumour suppressor gene are detected in up to 80 % of sporadic RCC (23) . VHL protein suppresses transcription of the vascular endothelial growth factor (VEGF). Thus VHL inactivation may result in VEGF overproduction and promotion of angiogenesis in RCC. A drug developed more than half a century ago and then abandoned due to teratogenicity, thalidomide, seems to have antiangiogenic activity and has been tested recently in some malignancies including RCC. As a monotherapy in the treatment of advanced RCC it has only limited activity. Altogether in nine phase II studies including 207 patients 12 (6 %) exhibited objective partial responses, but with considerable toxicity at high daily doses (24) .
Interferon is also weakly antiangiogenic, which may be improved with frequent dosing and by combination with other antiangiogenic agents. To investigate this issue Hernberg and colleagues (25) treated patients with metastatic RCC with a small dose IFNα -2b (0.9-1.2 MU) 3 times daily combined with thalidomide 100 mg/day for one week and 300 mg/d thereafter. The intention-to-treat response rate was 20 %. The authors concluded that the combination is feasible and active in advanced RCC, but the clinical benefit may remain small compared with that of IFN alone.
Pharmacologic agents that target specific molecules relevant to angiogenesis are now entering the clinic. The first such agents are inhibitors of vascular endothelial growth factor (VEGF), a potent endothelial cell mitogen or its receptor, KDR (kinase domain related). Yang and colleagues (26) tested whether the administration of a neutralizing anti-VEGF antibody could affect metastatic clear-cell carcinoma. In a phase II trial 116 patients were randomly assigned to placebo or to one of two different doses of the anti-VEGF antibody. The high-dose-antibody group had a statistically significant increase in the time to disease progression, as compared with the placebo group. No differences in overall survival were noted among the three groups, but crossover from placebo to antibody treatment was allowed, and survival was a secondary end-point. Only four patients in the study by Yang et al. had objective tumor responses to the anti-VEGF antibody, which is consistent with data suggesting that VEGF inhibition alone is unlikely to cause regression of mature blood vessels. Definitive phase III studies are now planned to ascertain the true clinical benefits of this promising treatment with VEGF inhibition in RCC.
NEW INVESTIGATIONAL AGENTS AND STRATEGIES
Encouraging results have been reported from a National Institute of Health pilot study examining nonmyeloablative stem cell transplantation in metastatic RCC (27) . Nineteen metastatic poor-prognosis RCC patients, unresponsive to other treatments received cyclophosphamide and fludarabine followed by allograft transplantation. Of the 19 patients 10 responded with three long-lasting complete responses. These results are exceptional in this highly treatment resistant disease and in spite of great toxicity the treatment should be further explored.
A recent report on multiple doses of CCI-779, a novel mammalian target of rapamycin kinase inhibitor in patients with advanced refractory RCC shows that totally new molecular approaches may be feasible and show promising antitumour activity in this disease (28) . Eight (7 %) of the 111 patients exhibited objective tumour responses and another 26 % minor responses, and median survival of the patients was 15 months. Additional studies of this agent either alone or in combination are warranted.
